Andromeda Biotech Acquires DiaPep277 Rights From Teva Pharmaceutical Industries Limited

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that it entered into an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva’s rights for Andromeda’s drug, DiaPep277®, for the treatment of Type 1 Diabetes.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC